Novavax and Moderna Compete in Dual COVID-19/Flu Vaccine Trials
Novavax, a smaller rival to Moderna and Pfizer in the COVID-19 vaccine market, may have a better chance of gaining market share with its updated coronavirus vaccine. As the vaccine landscape shifts to a commercial model, Novavax could carve out a market share by rapidly delivering doses to customers. This opportunity is crucial as the coronavirus is expected to stay, creating a potential market for annual vaccine sales. Novavax's presence in the vaccine marketplace now could also position it well for a potential combined flu/coronavirus vaccine product in the future. Investors should monitor Novavax's progress and consider the long-term rewards of its vaccine innovation.
